Intrathecal triamcinolone is more beneficial than IV mitoxantrone for the treatment of chronic progressive multiple sclerosis (MS)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1559, 2006-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration

By  

Current Pharmaceutical Design, Vol. 18, Iss. 29, 2012-10 ,pp. : 4564-4569

Bentham Science Publishers

Access to resources Recommend Favorite

Patients with secondary progressive multiple sclerosis (MS) may not benefit from treatment with IV immunoglobulin G (IVIG)

By  

Inpharma, Vol. 1, Iss. 1457, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Evaluation of mitoxantrone for the treatment of multiple sclerosis

By Jain K.K.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 5, 2000-05 ,pp. : 1139-1149

Informa Healthcare

Access to resources Recommend Favorite

Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 10, Iss. 6, 2011-09 ,pp. : 757-761

Bentham Science Publishers

Access to resources Recommend Favorite

Mitoxantrone: A Review of its Use in Multiple Sclerosis

By Scott L.J.   Figgitt D.P.  

CNS Drugs, Vol. 18, Iss. 6, 2004-01 ,pp. : 379-396

Adis International

Access to resources Recommend Favorite